Advertisement

Topics

Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder

2016-08-25 12:23:21 | BioPortfolio

Summary

It is a prospective randomized- placebo control crossover study to evaluate the effect of long acting tolterodine (anticholinergic) in improving and treating nocturnal incontinence in patient after radical cystectomy and orthotopic urinary diversion. patients will be randomly allocated into two groups. one will receive the drug and the other will receive placebo. continence status will be evaluated before and 4 weeks after treatment by the number of pads used and the ICIQ-UI short form questionnaire. This is followed by two weeks of drug washout then reevaluation of the continence status and each group will be crossed over and lastly will be evaluated again.

Description

Introduction:

Radical cystectomy (RC) and urinary diversion remain the gold standard for treatment of muscle invasive bladder cancer.1 The optimal goal is to control the malignancy, preserve renal function and optimize health related quality of life. Decision of urinary diversion selection has been changed in the last three decades from non-continent diversion to orthotopic neobladder (ONB), to maintain voiding pattern closely similar to normal pattern and to improve the overall health related quality of life (HRQOL).2 However, the continence status after ONB is affected by many factors, such as patient's age, mental status, intact and innervated external urethral sphincter, the reservoir capacity and pressure, presence of infection and the completeness of voiding.3 The recovery of continence status takes from six to 12 months after the operation to achieve day time continence which is regained earlier than nocturnal continence which takes 12 to 24 months.3 The reported day time continence ranges from 85 to 90% and NI in most series ranges from 20 to 40%.4- 7 in women, the reported incidence of day time and NI ranged from 68 to 100% and 26 to 89%, respectively.8- 11 Nocturnal incontinence is a major problem that affect HRQOL . In a multicenter study, individuals with ONB and NI have lower HRQOL, 12 this is similar to our data on female patients with ONB.2 Nocturnal incontinence may be due to patient and pouch causes. Loss of afferent input from the Detrusor muscle to the central nervous system is thought to account for the worsening of nocturnal continence.13 In a study, done by El Bahnasawy et al, to evaluate the factors affecting the NI after RC and ONB; higher pressure, positive urine culture, large post voiding residual volume, decreased maximal urethral pressure, decreased flow rate and patient compliance are associated with higher incidence of NI. However, on multivariate analysis, only post voiding residual volumes, frequency, and maximal amplitude of uninhibited contractions remained significantly associated with NI.14 Fifty percent of women with NI after RC and ONB have had pouch hyperactivity on urodynamic evaluation.15 To optimize nocturnal continence, patients are recommended to avoid sleeping pills and alcohol in the evening, to void before going to sleep, and to set up an alarm to void at least once during the night. Also proper treatment of infection is recommended.3 Up to 25% of patients reported an improved nocturnal continence with the use of imipramine hydrochloride 25 mg at bedtime. 14,16In a prospective randomized crossover study comparing 20 male enuretic patients with ileal ONB receiving oxybutynin versus verapamil, both groups showed improved urodynamic parameters and nocturnal continence status in 70% and 55% of patients, respectively.17 Ali-El-Dein et al, reported that treatment of female patients, who have NI after RC and ONB, with anticholinergic drugs (tolterodine or oxybutynin chloride) has associated with improvement and cure of NI in 36% and 23%, respectively.15 These data confirmed the efficacy of the anticholinergic use in treatment of NI after RC and ONB.

In the current study, we will study the role of long acting anticholinergic (tolterodine 4 mg) at bedtime in management of NI after RC and ONB through a prospective randomized placebo-controlled crossover study.

Material and methods:

Patients:

All patients for whom RC and ONB and attend for routine follow up at the outpatient clinic of Urology and Nephrology Center will be evaluated for eligibility of inclusion in this study.

Study design:

A single center prospective randomized placebo-controlled crossover study. It will be held in Urology and Nephrology Center, Mansoura University after approval of the local ethical committee. Patients meet the inclusion criteria will be included in the study. All patients will be evaluated by proper history, examination, BMI, ICIQ-UI Short Form, urine culture, serum creatinine and abdominal and pelvic ultrasound. Patients with positive urine culture will be treated by the appropriate antibiotic treatment till urine became sterile. Then, patients will be randomly allocated in 2 groups (1:1) by computer generated random numbers. The first group will receive long acting tolterodine (Incont LA, Adwia, Egypt) 4 mg at bedtime. The second group will receive placebo at bedtime. Both groups will be maintained on medication for 4 weeks. After that, both groups will be exposed to a period of two weeks of washout then crossed over to the alternate therapy.

Patients will be assessed for nocturnal incontinence by the number of episodes per week, number of pad used and ICIQ-UI short form questionnaire at the beginning of the study, after 4 weeks, after washout period then at the end of the study.

The ICIQ-UI short form is developed for assessing the prevalence, severity, impact on quality of life, and type of UI.19 The three scored items of the ICIQ-UI SF are:

1. How often do you leak urine? (0 ''Never,'' 1 '' About once a week or less often,'' 2 ''Two or three times a week,'' 3 ''About once a day,'' 4 ''Several times a day,'' 5 ''All the time''),

2. How much urine do you usually leak (whether you wear protection or not)? (0 ''None ,'' 2 ''A small amount,'' 4 ''A moderate amount,'' and 6 ''A large amount'')

3. Overall, how much does leaking urine interfere with your everyday life? (Visual analogue scale ranging from 0 ''Not at all'' to 10 ''A great deal''). Additional question is used to determine when urine leakage occurs. The answers result in a sum, with minimum score of 0, and maximum score of 21. Preliminary cut-off scores were set to 0 = ''no incontinence'' and ˃1= ''urinary incontinence.

Outcome measures:

The primary objective of the study is to evaluate the effect of tolterodine 4 mg on the nocturnal incontinence. This will be done by comparing the effect of the drug in the same group and by comparing its effect between different groups.

Sample size:

Assuming type I statistical error of 5 % and type II statistical error of 20 %, we designed our study to have a power of 80 %. Based on the results of the previous studies, the expected difference between the study and control group is 59- 70 %.15, 17The dropped out number of cases is suspected to be 10-20%. So, the sample size required to give significant difference is 60 in each arm.

Statistical analysis:

The ICIQ- UI score, number of pads and the number of nocturnal incontinence episodes will be expressed as mean± SD. Independent sample T-test will be used for comparison of means. All statistical tests will be done using Statistical Package for the Social Sciences 16.0 for Microsoft (SPSS, Inc., Chicago, Illinois, USA) with a p value of less than 0.05 considered significant.

The protocol is accepted by the local ethical committee of Faculty of medicine, Mansoura University ( Mansoura Faculty of Medicine- Institutional Research Board MFM-IRB) and given the number of R/16.07.51 Figure 1: study design and time schedule

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Conditions

Nocturnal Incontinence

Intervention

long acting tolterodine 4 mg, placebo

Status

Enrolling by invitation

Source

Mansoura University

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-08-25T12:23:21-0400

Clinical Trials [722 Associated Clinical Trials listed on BioPortfolio]

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

This study is being done to compare frequency of urination during the night when women take tolterodine tablets vs. when they take placebo tablets. We will also measure whether between th...

Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects

THVD-201 is a novel combination of a muscarinic antagonist (tolterodine) and a muscarinic agonist (pilocarpine).

Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity

Despite the great number of reports about the efficacy of oestrogens or antimuscarinics on OAB symptoms, so far no author has tried to investigate whether the concomitant administration of...

Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects

The muscarinic antagonist tolterodine is widely used treat urinary urge incontinence. Though acteylcholine is the primary excitatory neurotransmitter in the gastrointestinal tract, the pha...

Nocturnal Hypertension and Nocturia in African American Men

This study to obtain pilot data on Nocturnal Hypertension and Nocturia. In Dr. Victor's current NIH grant (Cut Your Pressure Too: The LA Barbershop Blood Pressure Study) the results show t...

PubMed Articles [8881 Associated PubMed Articles listed on BioPortfolio]

Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study.

Tolterodine is a nonselective muscarinic antagonist that is indicated for the overactive urinary bladder and other urinary difficulties. We developed and validated a simple, rapid and sensitive high-p...

Placebo analgesia persists during sleep: An experimental study.

Although placebo analgesia is a well-recognized phenomenon with important clinical implications, the possibility that placebo effects occur during sleep has received little attention. This experimenta...

A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism.

Congenital hyperinsulinism (CHI) is a rare disease characterized by recurrent severe hypoglycemia. In the diffuse form of CHI, pharmacotherapy is the preferred choice of treatment. Long-acting somatos...

Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.

Although second generation long-acting injectable antipsychotics (SG-LAIAs) have been approved and are widely used in adults, there is limited evidence for the use of long-acting formulations in child...

Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD.

Are inhaled long-acting muscarinic antagonists (LAMA) combined with long-acting β-agonists (LABA) associated with differences in the incidence of chronic obstructive pulmonary disease (COPD) exacerba...

Medical and Biotech [MESH] Definitions

An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE.

An insulin preparation that is designed to provide immediate and long term glycemic control in a single dosage. Biphasic insulin typically contains a mixture of REGULAR INSULIN or SHORT-ACTING INSULIN combined with a LONG-ACTING INSULIN.

One of the long-acting ANTIPSYCHOTIC AGENTS used for maintenance or long-term therapy of SCHIZOPHRENIA and other PSYCHOTIC DISORDERS.

Abnormal descent of a pelvic organ resulting in the protrusion of the organ beyond its normal anatomical confines. Symptoms often include vaginal discomfort, DYSPAREUNIA; URINARY STRESS INCONTINENCE; and FECAL INCONTINENCE.

Pain associated with a damaged PUDENDAL NERVE. Clinical features may include positional pain with sitting in the perineal and genital areas, sexual dysfunction and FECAL INCONTINENCE and URINARY INCONTINENCE.

More From BioPortfolio on "Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...


Searches Linking to this Trial